Severe atopic dermatitis and leflunomide: First clinical experience and highlights of pertinent experimental data

Dermatology Online Journal

Volumn 12, Issue 3, 2006, Pages

  Wozel, Gottfried ^a   Vitéz, Lilla ^a   Pfeiffer, Christiane ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; FLUCLOXACILLIN; HYDROXYZINE; LEFLUNOMIDE; LEVOCETIRIZINE; PREDNICARBATE; PREDNISOLONE;

ADULT; ATOPIC DERMATITIS; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG WITHDRAWAL; EOSINOPHIL; HUMAN; HUMAN TISSUE; LABORATORY TEST; LONG TERM CARE; MALE; PHOTOTHERAPY; PHYSICAL EXAMINATION; PSYCHOTHERAPY; REVIEW; SKIN PRURITUS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 33646439700     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Williams HC, Epidemiology of atopic dermatitis, Clin Exp Dermatol. 2000; 25:522-529.
2. Sidbury R, Hanifin JM, Systemic therapy of atopic dermatitis, Clinical Exp Dermatol. 2000; 25:559-566.
3. Thestrup-Pedersen K, Treatment principles of atopic dermatitis, J Eur Acad Dermatol Venereol. 2002;16-1-9.
4. Leung DYM, Bieber T, Atopic dermatitis, Lancet. 2003; 361:151-160.
5. Hanifin J, Gupta AK, Rajagopalan R, Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients, Br J Dermatol. 2002; 147:528-537.
6. Berth-Jones J, Damstra RJ, Golsch S et al., Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study, BMJ. 2003; 326:1367.
7. Meurer M, Fölster-Holst R, Wozel G et al., Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month-study, Dermatology. 2002; 205:271-277.
8. Thaci D, Long term management of childhood atopic dermatitis with calcineurin inhibitors, Hautarzt. 2003; 54:418-423.
9. Furue M, Terao H, Rikihisa W et al., Clinical dose and adverse effect of topical steroids in daily management of atopic dermatitis, Br J Dermatol. 2003; 148:128-133.
10. Harper JI, Ahmed I, Barclay G et al., Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy, Br J Dermatol. 2000; 142: 52-8.
11. Berth-Jones J, Takwale A, Tan E et al., Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial, Br J Dermatol. 2002; 147: 324-30.
12. Schmitt J, Wozel G, Pfeiffer C, Leflunomide as a novel treatment option in severe atopic dermatitis, Br J Dermatol. 2004; 150:1182-1185.
13. Leflunomide. In: AHFS Drug Information 2003. American Society of Health-System Pharmacists® , Bethesda 2003; 3639-3644
14. Kehrer T, Blümlein K, Wozel G, Eotaxin release is suppressed by the metabolite A 77 1726 of the novel immunomodulating agent leflunomide, Eur J Allergy Clin Immunol. 2001; 56 (S68):144.
15. Pfeiffer C, Kehrer T, Wozel G, Suppression of eotaxin expression and release by leflunomide's active metabolite A77 1726 is not reversed by uridine, XXIII EAACI congress, 2004; 12-16.06. Amsterdam
16. Amerio P, Frezzolini A, Feliciani C et al., Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications, Current drug Targets-Inflammation and Allergy. 2003; 2:81-94.
17. Breuer K, Kapp A, Werfel T, Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age, Allergy. 2001; 56: 780-784.
18. Breedveld FC, Dayer JM, Leflunomide: mode of action in the treatment of rheumatoid arthritis, Ann Rheum Dis. 2000; 59:841-849.
19. Rückemann K, Fairbanks L, Carrey EA et al., Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated lymphocytes from healthy humans, J Biol Chem. 1998; 273:21682-21691.
20. Siemasko KF, Chong AS, Williams JW et al., Regulation of B- cell function by the immunosuppressive agent leflunomide, Transplantation. 1996; 61:635-42.
21. Hamilton LC, Vojnovic I, Warner TD, A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-specific manner, Br J Pharmacol. 1999; 127:1589-1596.
22. Kaltwasser JP, Behrens F, Leflunomide :long-term clinical experience and new uses, Expert Opin Pharmacother. 2005; 6: 787-801.
23. Fox RI, Mechanism of action of leflunomide in rheumatoid arthritis, J Rheumatol. 1998; 25:S(53):20-26.
24. Reich K, Hummel KM, Beckmann I et al., Treatment of severe psoriasis and psoriatic arthritis with leflunomide, Br J Dermatol. 2002; 146: 335-6.
25. Schmitt J, Wozel G, Psoriasisarthritis, J Deutsch Dermatol Ges. 2004; 2:763-6.
26. Nousari HC, Anhalt GJ, Bullous pemphigoid treated with leflunomide, Arch Dermatol. 2000; 136:1204-1205.
27. Scarpato S, Tirri E, Successful treatment of SAPHO syndrome with leflunomide, Clin Exp Rheumatol .2005; 23:731.
28. Feng H, Li XY, Zheng JR, Gao JW, Xu LF, Tang MY, Inhibition of nuclear Factor-kB signaling pathway by leflunomide or triptolide also inhibits the anthralin- induced inflammatory response but does not affect keratinocyte growth inhibition, Biol Pharm Bull. 2005; 28(9):1597-1602.
29. Kagami S, Kakinuma T, Saeki H et al., Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis, Clin Exp Immunol. 2003; 134:309-313.
30. Manna SK, Mukhopadhyay A, Aggarwal BB, Leflunomide inhibits TNF-induced cellular responses: effects on NFκB, activator protein-1, c-Jun Nterminal protein kinase, and apoptosis, J Immunol. 2000; 165:5962-5969.
31. Sriramarao P, DiScipio RG, Cobb RR et al., VCAM-1 is more effective than MAdCAM-1 in supporting eosinophil rolling under conditions of shear flow, Blood. 2000; 95(2):592-601.
32. Hohki G, Terada N, Hamano N et al., The effects of eotaxin on the surface adhesion molecules of endothelial cells and on eosinophil adhesion to microvascular endothelial cells, Biochemical and Biophysical Research Communications. 1997; 241:136-141.
33. Sallusto F, Mackay CR, Lanzavecchia A, Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells, Science. 1997; 277: 2005-2007.
34. Wozel G, Pfeiffer C, Leflunomid - ein neues Medikament zur pharmakologischen Immunmodulation, Hautarzt. 2002; 53:309-315.
35. Wollenberg A, Zoch C, Wetzel S et al., Predisposing factors and clinical features of eczema herpeticum: a retrospective analyzing 100 cases, J Am Acad Dermatol. 2003; Aug; 49 (2):198-205.